A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT06208150
Trial Phases:	Phase III	Protocol IDs:	64407564MMY3009 (primary) NCI-2024-04424 2022-502446-27-00 64407564MMY3009
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Janssen Research & Development, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06208150

Summary

The purpose of this study is to compare the effectiveness of either talquetamab plus
pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab,
pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone
(PVd).

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.